

ARTRYA<sup>TM</sup>

# CORONARY ARTERY DISEASE

## WE SEE YOU



# AI to rapidly assess chest pain

Artrya partners with clinics receiving chest pain patients to deliver new models of cardiovascular care based on AI. Effortlessly integrate plaque characteristics of high prognostic value into the evaluation of coronary artery disease.


Salix Coronary Anatomy (SCA) enables clinicians to easily see the type and volume of arterial plaque detected through coronary computed tomography angiography (CCTA), facilitating the accurate stratification of chest pain patients within minutes.

## Rapid patient discharge

Quickly determine patients with minimal to zero coronary artery disease, with the confidence there are no underlying plaque features that could cause future major adverse cardiac events.

## Efficient patient intake

Catch the early warning signs of a potential heart attack. Effectively rule in at-risk patients with acute or atypical chest pain that warrant further investigation and therapy.



artrya.com

## For clinicians

Change how coronary artery disease is diagnosed. By illustrating atherosclerotic plaque features clinicians can better guide a patient's therapeutic treatment. To bridge the gap between hard facts on CCTA and data reporting processes, SCA provides the tool to reduce manual work-up, helping clinicians to improve patient classification through the effective integration of plaque features into clinical decision-making.

## For patients


Seeing is believing. Patients receive easy-to-understand, meaningful and comprehensive information about their heart health risks. With SCA, clinicians can share a visual 3D model of a patient's heart to help them understand the extent of their coronary artery disease.

## For payers

Traditional models see too many patients indicated for multiple tests and admitted for expensive observation stays. There is a better way. Clinicians can use precision data to determine appropriate testing, treatment and admittance, while filtering out false positives to focus on patients who require critical preventative care.

**ARTRYA SALIX**





## AI tool to support coronary artery disease diagnosis

### Comprehensive Report

Clinicians can access a holistic patient report to consider during their interpretation and diagnosis, including assessments of major arteries (LM, LCX, LAD and RCA) and sub branches. The report clearly shows an unprecedented combination of imaging features comprising plaque characteristics, total plaque burden, stenosis severity and calcium score, encouraging the inclusion of these valuable data points during patient diagnosis.

### Workflow integrated

Patient scans can be sent directly to a second clinician for additional assessment, providing further certainty in complex cases.

### Clinician analysis

Advanced functionality delivers centreline tracking, segmenting and annotating disease with complementary raw data available. As disease is located SCA quickly populates coronary findings. Insights are fully editable to coincide with clinician impression.

### Assessment within 15 minutes

The Salix algorithm has been trained on thousands of existing scans. From one scan, each artery is assessed and illustrated in a 3D model. The plaque features are presented on a patient report in real-time, at the point of care. AI-driven analysis can substantially shorten post-processing and reporting time and SCA does this within 15 minutes.


## How it works

SCA is cloud-based, secured with a direct VPN from PACS to cloud to maintain the highest level of security. SCA is accessed by a unique login using a secured web browser with no on-site hardware requirements.

Users can get started immediately through automatic access to the software as no installation is required. Users will also have instant access to the latest updates and patches without the need to install, incur downtime or disrupt their workflow.

### Indications for use

SCA is an interactive tool for viewing and assessing CCTA data and may help trained clinicians determine the presence and extent of coronary plaques and stenosis. It may also help quantify calcifications (calcium scoring) in patients who underwent CCTA for evaluation of coronary artery disease.






## Expert Cardiologist discusses the value of SCA

**“SCA is a decision-support tool to enable clinicians in the accurate risk assessment of chest pain patients with suspected CAD. SCA will greatly help our ability to diagnose, report and also treat coronary artery disease. Ultimately, it will lead to more effective and personalised medical treatment.”**

Professor Girish Dwivedi, Harry Perkins Institute of Medical Research, Wesfarmers Chair in Cardiology, Consultant Cardiologist, Fiona Stanley Hospital, Chief Scientific Officer, Artrya.



## Artrya - Your partner in AI-driven healthcare

Artrya is changing how the world diagnoses, and therefore treats, coronary artery disease. We are doing it in a way that is better for patients, healthcare professionals and health systems. We partner with healthcare delivery systems to implement new cardiac care models that can rule out (or in) coronary artery disease at speed, for patients presenting with chest pain.

Salix Coronary Anatomy, is an AI-based diagnostic support solution that empowers clinicians to quickly assess cardiac CT scans and accurately determine the presence and extent of atherosclerotic plaque and plaque features in patients suspected of coronary artery disease. With fast and accurate detection, precise preventative therapy can reduce the risk of future heart attack.

## ARTRYA SALIX

SCA is listed on the Australian Register of Therapeutic Goods ID 347719. Product representations are for the approved product in Australia. Currently, this product is not approved in the U.S. or UK and imagery is presented for reference only. Product use outside of Australia is for investigational purposes only. Stock: PB190301/5

[artrya.com](https://artrya.com)